US EditionYolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
- YolTech Therapeutics announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for YOLT-101, a therapy for treating heterozygous familial hypercholesterolemia .
- YOLT-101 is designed to provide a single-dose treatment that durably reduces blood LDL-C, employing hpABE5 for precise A•T to G•C base conversion without inducing DNA double-strand breaks.
- The FDA IND clearance represents a significant milestone for YolTech Therapeutics.
- The ongoing investigator-initiated trial has shown a favorable safety profile and robust LDL-C-lowering effects for YOLT-101.
Insights by Ground AI
Does this summary seem wrong?
64 Articles
64 Articles
All
Left
8
Center
23
Right
5
Rutland Herald+63 Reposted by 63 other sources
YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for YOLT-101, an…
Coverage Details
Total News Sources64
Leaning Left8Leaning Right5Center23Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 22%
C 64%
14%
Factuality
To view factuality data please Upgrade to Premium
